Adenosine Therapeutics gets cash for DES (drug-eluting stent) development
This article was originally published in Clinica
Executive Summary
US pharmaceutical firm Adenosine Therapeutics has joined the growing number of manufacturers hoping to cash in on the lucrative drug-eluting stent (DES) sector for preventing restenosis - the re-clogging of arteries.